A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Peking University

Status: Not yet enrolling

Conditions: Esophageal Cancer

Treatments: Drug: Camrelizumab

Study type: Observational

Funder types: Other

Identifiers

NCT04616040

LION-EC

Details and patient eligibility

About

The trial is a multi-center, open, observational registration study, which aims to evaluate the safety and efficacy of Camrelizumab (anti-PD-1 antibody) in the treatment of Chinese patients with advanced esophageal cancer in the real world.

Enrollment: 1,030 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Sign informed consent and voluntarily participate in this study.

2. Unresectable locally advanced/recurring or distant metastatic esophageal cancer patients confirmed by histology or cytology (AJCC 8th edition);

   • Unresectable locally advanced patients who are unable or unable to receive radical treatment (including radical radio chemotherapy or radical radiotherapy, etc.) may be considered for inclusion;
   • Patients who progress or relapse after neoadjuvant or adjuvant therapy may also be considered for inclusion;

3. Age ≥ 18 years old;

4. The investigator determines that the patient can receive Camrelizumab as a single agent or combination therapy.

Exclusion criteria

1. Evidence suggests that the patient is pregnant or breastfeeding;
2. Other drug blinded clinical trials are currently underway;
3. Other situations that are not suitable for inclusion in this study.

Trial design

1,030 participants in 1 patient group

unresectable locally advanced/recurrent or metastatic esophageal cancer

Treatment:

Drug: Camrelizumab